Study of CTX-471 as a Monotherapy or in Combination With Pembrolizumab in Patients Post PD-1/PD-L1 Inhibitors in Metastatic or Locally Advanced Malignancies
Compass Therapeutics
Compass Therapeutics
AstraZeneca
Sotio Biotech Inc.
Neonc Technologies, Inc.
Radiopharm Theranostics, Ltd
MacroGenics
MacroGenics
ImmunityBio, Inc.
GV20 Therapeutics
DualityBio Inc.
Incyte Corporation
OncoHost Ltd.
Novelty Nobility, Inc.
Hangzhou DAC Biotechnology Co., Ltd.
Pfizer
Hoffmann-La Roche
Incyte Corporation
Incyte Corporation
Marengo Therapeutics, Inc.
OncoC4, Inc.
Theratechnologies
Seagen Inc.
AstraZeneca
Salubris Biotherapeutics Inc
Pfizer
Xencor, Inc.
Pfizer
Exelixis
Fate Therapeutics
Fate Therapeutics
Xencor, Inc.
Xencor, Inc.
Xencor, Inc.
Incyte Corporation
Opna Bio LLC
Genocea Biosciences, Inc.
AbbVie
AbbVie
Incyte Corporation
Incyte Corporation
SpeciCare
Incyte Corporation
Guangdong Zhongsheng Pharmaceutical Co., Ltd.
MultiVir, Inc.
Incyte Corporation
Celgene
Santa Maria Biotherapeutics
Novartis
ImmunoGen, Inc.
INSYS Therapeutics Inc